{"pmid":32294236,"title":"Exaggerated information and COVID-19 outbreak.","text":["Exaggerated information and COVID-19 outbreak.","We read the article on \"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures\" with a great interest [1]. Ioannidis noted that \"It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions [1].\"","Eur J Clin Invest","Sriwijitalai, Won","Wiwanitkit, Viroj","32294236"],"abstract":["We read the article on \"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures\" with a great interest [1]. Ioannidis noted that \"It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions [1].\""],"journal":"Eur J Clin Invest","authors":["Sriwijitalai, Won","Wiwanitkit, Viroj"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294236","week":"202016|Apr 13 - Apr 19","doi":"10.1111/eci.13226","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664266295653171200,"score":8.233237,"similar":[{"pmid":32202659,"title":"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","text":["Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions.","Eur J Clin Invest","Ioannidis, John P A","32202659"],"abstract":["The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions."],"journal":"Eur J Clin Invest","authors":["Ioannidis, John P A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202659","week":"202013|Mar 23 - Mar 29","doi":"10.1111/eci.13223","source":"PubMed","weight":0,"_version_":1663352133642092545,"score":379.1013},{"pmid":32191341,"title":"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","text":["Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions.","Eur J Clin Invest","Ioannidis, John P A","32191341"],"abstract":["The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions."],"journal":"Eur J Clin Invest","authors":["Ioannidis, John P A"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191341","week":"202012|Mar 16 - Mar 22","doi":"10.1111/eci.13222","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1663352133765824512,"score":379.1013},{"pmid":32293030,"title":"Letter to the Editor Re: Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures.","text":["Letter to the Editor Re: Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures.","Dr. Ioannidis may cause irreparable harm from recent publications. Novel coronavirus, by definition, arrives without precedence and therefore the reliable data Ioannidis craves. The unshakable facts regarding the Covid-19 consists of the number of deaths, country populations, and the dataset from the Diamond Princess cruise.","Eur J Clin Invest","Reichmann, James P","32293030"],"abstract":["Dr. Ioannidis may cause irreparable harm from recent publications. Novel coronavirus, by definition, arrives without precedence and therefore the reliable data Ioannidis craves. The unshakable facts regarding the Covid-19 consists of the number of deaths, country populations, and the dataset from the Diamond Princess cruise."],"journal":"Eur J Clin Invest","authors":["Reichmann, James P"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293030","week":"202016|Apr 13 - Apr 19","doi":"10.1111/eci.13224","source":"PubMed","weight":0,"_version_":1664266295668899840,"score":191.46977},{"pmid":32294248,"title":"Improving Communication About COVID-19 and Other Emerging Infectious Diseases.","text":["Improving Communication About COVID-19 and Other Emerging Infectious Diseases.","John Ioannidis writes about the harm caused by misinformation about COVID-19.(1) We draw from communication research to offer best practices for reducing misinformation, disseminating accurate health information, and promoting prevention and control recommendations. We recommend three strategies that medical, public health, and scientific professionals working with government officials, clinicians, media commentators, and in other contexts around the world can use to improve communication about outbreaks.","Eur J Clin Invest","Jacobsen, Kathryn H","Vraga, Emily K","32294248"],"abstract":["John Ioannidis writes about the harm caused by misinformation about COVID-19.(1) We draw from communication research to offer best practices for reducing misinformation, disseminating accurate health information, and promoting prevention and control recommendations. We recommend three strategies that medical, public health, and scientific professionals working with government officials, clinicians, media commentators, and in other contexts around the world can use to improve communication about outbreaks."],"journal":"Eur J Clin Invest","authors":["Jacobsen, Kathryn H","Vraga, Emily K"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294248","week":"202016|Apr 13 - Apr 19","doi":"10.1111/eci.13225","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664266295798923264,"score":127.07268},{"pmid":32250244,"title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","text":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.","Elife","Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias","32250244"],"abstract":["The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population."],"journal":"Elife","authors":["Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250244","week":"202015|Apr 06 - Apr 12","doi":"10.7554/eLife.57278","keywords":["epidemiology","global health","viruses"],"source":"PubMed","locations":["ACE-1","AngII"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136227880961,"score":102.784805}]}